Interleukin-1 receptor type I (IL-1RI) is a critical component of the immune system, serving as the primary receptor for the pro-inflammatory cytokines IL-1α and IL-1β. These cytokines are involved in a broad spectrum of biological processes, including inflammation, fever response, and hematopoiesis. Upon binding to IL-1RI, these cytokines initiate a cascade of intracellular signaling events, chiefly through the activation of NF-κB and MAP kinase pathways. This leads to the transcription of genes associated with inflammation and immune responses. The specificity and sensitivity of IL-1RI-mediated signaling are critical for ensuring appropriate immune responses, and any dysregulation can lead to pathological conditions. For instance, overactivation can contribute to chronic inflammatory diseases, while underactivation might result in an impaired immune response to pathogens.
Activators of IL-1RI are molecules or compounds that enhance the expression, stability, or signaling capacity of IL-1RI. These activators can function by promoting the transcription or translation of the IL-1RI gene, stabilizing the receptor protein, or potentiating its interaction with IL-1 cytokines or intracellular signaling adaptors. The presence of IL-1RI activators can significantly influence immune and inflammatory dynamics, amplifying or fine-tuning the cellular responses to inflammatory cues or infections. Delving into the domain of IL-1RI activators offers profound insights into the intricate regulation of inflammatory signaling. As the elaborate network of immune responses continues to be unraveled, the role of IL-1RI and its activators stands out, shedding light on the molecular mechanisms that underpin the body's defense mechanisms and the delicate balance of inflammation and immune regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
Bacterial endotoxin that activates Toll-like receptor 4 (TLR4) leading to NF-κB activation and inflammatory cytokine production. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C leading to activation of multiple pathways including NF-κB. | ||||||
Polyinosinic-polycytidylic acid potassium salt | 31852-29-6 | sc-202767 | 5 mg | $198.00 | ||
Mimics viral dsRNA and activates TLR3 leading to interferon and cytokine production. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Activates TLR7 leading to production of type I interferons and other cytokines. | ||||||
Zymosan | 9010-72-4 | sc-296863 sc-296863A | 100 mg 1 g | $99.00 $599.00 | 1 | |
Derived from yeast cell walls and activates TLR2/6 and dectin-1 leading to NF-κB activation. | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
Synthetic lipopeptide that activates TLR1/2 leading to NF-κB activation. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Activates TLR7 and TLR8 leading to production of type I interferons and other cytokines. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
Can modulate IL-1RI expression, often reducing it, as part of its anti-inflammatory effects. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Can modulate IL-1RI expression, potentially as part of its role in inflammation and fever generation. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Can modulate IL-1RI expression, potentially as part of its effects on immune cell differentiation. | ||||||